Update shared on05 Sep 2025
With consensus forecasts for both future P/E (25.87x) and annual revenue growth (14.5%) unchanged, analysts have maintained Gland Pharma’s fair value at ₹1863.
What's in the News
- Gland Pharma received USFDA approval for Vasopressin in 5% Dextrose Injection (40 Units/100 mL); tentative approval granted for 20 Units/100 mL variant, targeting a $45 million US market.
- USFDA approved Gland Pharma's Norepinephrine Bitartrate in 5% Dextrose Injection (4 mg/250 mL and 8 mg/250 mL); company is First-to-File and eligible for 180 days of exclusivity in the $55 million US market.
- USFDA approved Cangrelor for Injection (50mg/vial), with Gland Pharma securing 180 days of generic exclusivity, targeting a $122 million US market.
- Private equity groups Brookfield and EQT are in advanced discussions to acquire Gland Pharma from Fosun Group, with a potential transaction value of up to $3 billion if the open offer is fully subscribed; rising share price and industry headwinds may affect deal outcome.
- Board meetings were held to approve quarterly financial results and to grant stock options to a key employee.
Valuation Changes
Summary of Valuation Changes for Gland Pharma
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1863.
- The Future P/E for Gland Pharma remained effectively unchanged, at 25.87x.
- The Consensus Revenue Growth forecasts for Gland Pharma remained effectively unchanged, at 14.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.